Select Page

Los Angeles, CA, August 25, 2017 (Newswire) –Robert Gadimian, owner of privately held Rophe Pharma, announced his company has been assigned product code RPHE-7193 for an exciting new treatment to fight hair loss. The treatment comes in the form of a topical solution using hydralazine. The background for hydralazine in RPHE-7193 is almost the same as minoxidil, the active substance in RogaineHydralazine, like minoxidil, is a blood pressure drug that exhibited the side effect of promoting hair growth.

NEW HOPE FOR HAIR LOSS SUFFERERS

According to Robert Gadimian, based on the preliminary results hydralazine is demonstrating to be a superior hair growth compound compared to minoxidil. In the exploratory study that is going on with 12 men, hair growth is being observed after 4-8 weeks of use in men up to age 65. The two already approved drugs for male pattern baldness (MPB), Rogaine and Propecia, take a much longer time to show their efficacy. So clearly there are men still hoping for more effective hair growth treatments such as RPHE-7193. Rogaine and Propecia have not been studied in men above age 411 but Gadimian is testing RPHE-7193 in that age group. Most of the men who suffer from hair loss are above age 41 — a fact the FDA told the Rogaine developers during its development. [RG1]

MINIMIZING SCALP IRRITATION

RPHE-7193 does not contain alcohol or polyethylene glycol, two solvents in Rogaine that cause skin irritation and sensitivity; hence RPHE-7193 is expected to have a better skin related safety profile than Rogaine.

ROPHE PHARMA’S NEW PRODUCT TO FIGHT HAIR LOSS

According to the America Hair Loss Association, MPB – also referred to as androgenetic alopecia — accounts for more than 95% of hair loss in men. By the age of 35, two-thirds of American men will experience some degree of appreciable hair loss; by the age of fifty, approximately 85% of men will contend with significantly thinning hair. Approximately 25% of men who suffer with MPB began the painful process of losing their hair before reaching the age of 21. For men unhappy with MPB the effects can be wide-ranging and affect quality of life, both personal and professional. In spite of this widespread issue, no drug has been able to satisfactorily solve MPB in men. The available treatments include Rogaine, which according to some, has a non-satisfactory hair growth effect, takes a long time to work and has skin irritation side-effects or Propecia that should be taken for a long time (around 8-12 months) to see the effectas well as having some sexual side-effects for men.

AVOID FALSE PROMISES AND SEEK FDA APPROVED PRODUCTS

Rogaine and Propecia currently constitute the only two FDA-approved drugs for hair loss treatment. Meanwhile millions of hair loss sufferers remain eagerly poised for the introduction of legitimate and approved pharmaceutical drugs to expand their range of choices. This market demand has led to many fake treatments on the market.  A cautionary recommendation by the American Hair Loss Association addresses questionable hair loss treatment therapies:

“You’ve all seen the ads in the back of men’s magazines, you’ve heard the commercials on the radio and you’ve seen the infomercials promoting miracle treatments for hair loss. The bottom line is that the vast majority of advertised ‘treatments’ do not work for the prevention and treatment of hair loss. If a hair loss treatment is not approved by the FDA or recommended by the American Hair Loss Association, chances are you are wasting your precious time and money.”

Gadimian announced that Rophe Pharma is hoping to bring to market the desperately needed hair growth treatment that will work for most men in all age groups.

1         Source: Summary basis of approval for Rogaine and Propecia​

[RG1]I moved this sentence up.